Accomplished Senior Safety Science Specialist with a proven track record for enhancing workflow management and quality review processes. Expert in clinical trials case processing and mentoring, achieving a quality review percentage above 99%. Skilled in Veeva document management and SAE reconciliation, demonstrating a robust blend of technical prowess and leadership excellence. Results-oriented individual with a passion for continuous learning and innovation. Known for leveraging analytical thinking and creativity to solve problems and deliver high-impact solutions in fast-paced environments. Experienced in fast-paced environments and adaptable to last-minute changes. Thrives under pressure and consistently earns high marks for work quality and speed.
Senior Safety Science Specialist at Fortrea (Labcorp ), Bangalore- MAR 2023 to till date.
Safety Science Specialist at Labcorp (Covance), Bangalore- MAR 2021 to MAR 2023
Operations Specialist I at IQVIA, Bangalore – DEC 2017 to MAR 2021
Experience Summary:
• 6. 11 years of experience in pharmacovigilance and drug safety.
• Experience in coding of events, medical history by using MEDRA dictionaries.
• End to End Serious and Non-Serious Case Handling/Quality Review of legal, Spontaneous, Solicited and Clinical Trial cases.
• End to End Pharmacovigilance Experience in book in, triaging, Data Entry, Medical coding, Quality Review, Safety narrative, Finalization, Regulatory report generation as per timelines.
• To perform Pharmacovigilance activities per project requirement including but not limited to, collecting and tracking incoming Adverse Events(AE)/endpoint information; determining initial/update status of incoming events; database entry; coding AE and Products, writing narratives.
Therapeutic Experience
· Cardio Metabolic: Metabolic and Cardiovascular Risk - Hypertension (Phase IV)
· Immune Mediated Inflammatory Disease (IMID): Dermatologic - Psoriasis (Phase IV), Inflammatory Bowel - Crohn’s disease (Phase IV), Ulcerative colitis (Phase IV), Systemic IMID - Psoriatic arthritis (Phase IV), Ankylosing spondylitis (Phase IV)
· Oncology: Hematologic Malignancies – Multiple Myeloma (Phase IV)
· Hematology: Lymphoma – Follicular lymphoma (Phase II)
· Oncology: Lung Cancer – NSCLC (Non-Small Cell Lung Cancer Phase II
· Hematology: Plasma Cell Dyscrasias – Multiple Myeloma Phase II
· Hematology: Lymphoma – Diffuse large B cell lymphoma (DLBCL) Phase II and Phase IIIVaccine (Covid 19 Vaccine)
Diploma In Clinical Research, NIDA Certification
I hereby declare that the above information provided is true to the best of my knowledge and belief.